Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain

N. D. Volkow, J. S. Fowler, G. J. Wang, S. L. Dewey, D. Schlyer, R. MacGregor, J. Logan, D. Alexoff, C. Shea, Robert Hitzemann, B. Angrist, A. P. Wolf

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

Carbon-11-raclopride has been successfully utilized with PET to assess changes in endogenous dopamine concentration after pharmacological intervention in the living baboon brain. For similar studies to be done in humans, measurements of 11C-raclopride with no intervention need to be reproducible. In order to test the reproducibility (test-retest) of 11C- raclopride binding in the human brain, we performed repeated studies on two different days. Studies were done in five normal controls with no pharmacological intervention. Time-activity (%dose/cc) curves for 11C- raclopride in the basal ganglia (BG) and cerebellum (CBL) were highly reproducible with an average difference in peak uptake for repeated studies in the same individual of 4%. The BG to CBL ratio for the average activity concentration between 30 and 60 min showed differences that ranged from -7% to 8% between the repeated studies. Graphical analysis to obtain the distribution volume revealed intrasubject values that ranged from -9% to 7% for the ratio of the distribution volume in BG to that in CBL. These studies demonstrate that in order to use 11C-raclopride to measure an individual's change in relative dopamine concentration secondary to pharmacological or behavioral intervention, a change in striatal 11C-raclopride binding in excess of 10% is required.

Original languageEnglish (US)
Pages (from-to)609-613
Number of pages5
JournalJournal of Nuclear Medicine
Volume34
Issue number4
StatePublished - 1993
Externally publishedYes

Fingerprint

Raclopride
Carbon
Brain
Basal Ganglia
Cerebellum
Pharmacology
Dopamine
Corpus Striatum
Papio

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Volkow, N. D., Fowler, J. S., Wang, G. J., Dewey, S. L., Schlyer, D., MacGregor, R., ... Wolf, A. P. (1993). Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. Journal of Nuclear Medicine, 34(4), 609-613.

Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. / Volkow, N. D.; Fowler, J. S.; Wang, G. J.; Dewey, S. L.; Schlyer, D.; MacGregor, R.; Logan, J.; Alexoff, D.; Shea, C.; Hitzemann, Robert; Angrist, B.; Wolf, A. P.

In: Journal of Nuclear Medicine, Vol. 34, No. 4, 1993, p. 609-613.

Research output: Contribution to journalArticle

Volkow, ND, Fowler, JS, Wang, GJ, Dewey, SL, Schlyer, D, MacGregor, R, Logan, J, Alexoff, D, Shea, C, Hitzemann, R, Angrist, B & Wolf, AP 1993, 'Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain', Journal of Nuclear Medicine, vol. 34, no. 4, pp. 609-613.
Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schlyer D, MacGregor R et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. Journal of Nuclear Medicine. 1993;34(4):609-613.
Volkow, N. D. ; Fowler, J. S. ; Wang, G. J. ; Dewey, S. L. ; Schlyer, D. ; MacGregor, R. ; Logan, J. ; Alexoff, D. ; Shea, C. ; Hitzemann, Robert ; Angrist, B. ; Wolf, A. P. / Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. In: Journal of Nuclear Medicine. 1993 ; Vol. 34, No. 4. pp. 609-613.
@article{9218a720fed047d094997f92481807d0,
title = "Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain",
abstract = "Carbon-11-raclopride has been successfully utilized with PET to assess changes in endogenous dopamine concentration after pharmacological intervention in the living baboon brain. For similar studies to be done in humans, measurements of 11C-raclopride with no intervention need to be reproducible. In order to test the reproducibility (test-retest) of 11C- raclopride binding in the human brain, we performed repeated studies on two different days. Studies were done in five normal controls with no pharmacological intervention. Time-activity ({\%}dose/cc) curves for 11C- raclopride in the basal ganglia (BG) and cerebellum (CBL) were highly reproducible with an average difference in peak uptake for repeated studies in the same individual of 4{\%}. The BG to CBL ratio for the average activity concentration between 30 and 60 min showed differences that ranged from -7{\%} to 8{\%} between the repeated studies. Graphical analysis to obtain the distribution volume revealed intrasubject values that ranged from -9{\%} to 7{\%} for the ratio of the distribution volume in BG to that in CBL. These studies demonstrate that in order to use 11C-raclopride to measure an individual's change in relative dopamine concentration secondary to pharmacological or behavioral intervention, a change in striatal 11C-raclopride binding in excess of 10{\%} is required.",
author = "Volkow, {N. D.} and Fowler, {J. S.} and Wang, {G. J.} and Dewey, {S. L.} and D. Schlyer and R. MacGregor and J. Logan and D. Alexoff and C. Shea and Robert Hitzemann and B. Angrist and Wolf, {A. P.}",
year = "1993",
language = "English (US)",
volume = "34",
pages = "609--613",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "4",

}

TY - JOUR

T1 - Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain

AU - Volkow, N. D.

AU - Fowler, J. S.

AU - Wang, G. J.

AU - Dewey, S. L.

AU - Schlyer, D.

AU - MacGregor, R.

AU - Logan, J.

AU - Alexoff, D.

AU - Shea, C.

AU - Hitzemann, Robert

AU - Angrist, B.

AU - Wolf, A. P.

PY - 1993

Y1 - 1993

N2 - Carbon-11-raclopride has been successfully utilized with PET to assess changes in endogenous dopamine concentration after pharmacological intervention in the living baboon brain. For similar studies to be done in humans, measurements of 11C-raclopride with no intervention need to be reproducible. In order to test the reproducibility (test-retest) of 11C- raclopride binding in the human brain, we performed repeated studies on two different days. Studies were done in five normal controls with no pharmacological intervention. Time-activity (%dose/cc) curves for 11C- raclopride in the basal ganglia (BG) and cerebellum (CBL) were highly reproducible with an average difference in peak uptake for repeated studies in the same individual of 4%. The BG to CBL ratio for the average activity concentration between 30 and 60 min showed differences that ranged from -7% to 8% between the repeated studies. Graphical analysis to obtain the distribution volume revealed intrasubject values that ranged from -9% to 7% for the ratio of the distribution volume in BG to that in CBL. These studies demonstrate that in order to use 11C-raclopride to measure an individual's change in relative dopamine concentration secondary to pharmacological or behavioral intervention, a change in striatal 11C-raclopride binding in excess of 10% is required.

AB - Carbon-11-raclopride has been successfully utilized with PET to assess changes in endogenous dopamine concentration after pharmacological intervention in the living baboon brain. For similar studies to be done in humans, measurements of 11C-raclopride with no intervention need to be reproducible. In order to test the reproducibility (test-retest) of 11C- raclopride binding in the human brain, we performed repeated studies on two different days. Studies were done in five normal controls with no pharmacological intervention. Time-activity (%dose/cc) curves for 11C- raclopride in the basal ganglia (BG) and cerebellum (CBL) were highly reproducible with an average difference in peak uptake for repeated studies in the same individual of 4%. The BG to CBL ratio for the average activity concentration between 30 and 60 min showed differences that ranged from -7% to 8% between the repeated studies. Graphical analysis to obtain the distribution volume revealed intrasubject values that ranged from -9% to 7% for the ratio of the distribution volume in BG to that in CBL. These studies demonstrate that in order to use 11C-raclopride to measure an individual's change in relative dopamine concentration secondary to pharmacological or behavioral intervention, a change in striatal 11C-raclopride binding in excess of 10% is required.

UR - http://www.scopus.com/inward/record.url?scp=0027406130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027406130&partnerID=8YFLogxK

M3 - Article

C2 - 8455077

AN - SCOPUS:0027406130

VL - 34

SP - 609

EP - 613

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 4

ER -